ADVERTISEMENT
News
BioStem Technologies
07/16/2024
BioStem announced that the Institute Review Board (IRB) approved a clinical study to evaluate the efficacy of AmnioWrap2 (AW2) in patients with DFU. Once BioStem completes the study, the company plans to commercially advance AW2 with expanded Payer Insurance Coverage within the DFU market.